Basic Stugeron Information

• INN (International Nonproprietary Name): Cinnarizine
• Brand Names Available In United States: not specified
• ATC Code: N07CA02
• Forms & Dosages: Oral tablet 25 mg most common; extended‑release tablet (rare, some markets); syrup/suspension (select regions)
• Manufacturers In United States: not specified
• Registration Status In United States: United States lacks broad FDA‑registered Stugeron presence; clinicians more commonly use meclizine and dimenhydrinate
• OTC / Rx Classification: not specified

Key Findings From Recent Trials

Major 2022–2024 Studies

What did the newest trials actually show about cinnarizine for motion sickness and vertigo?

Recent randomized studies published through mid‑2024 focused largely on motion sickness prevention and symptomatic vertigo and compared cinnarizine 25 mg regimens versus placebo and common antihistamines.

Meta‑analyses that pooled adult trials emphasized consistent benefit for travel‑related nausea and chronic vestibulopathy.

Main Outcomes

Which outcomes were clinically meaningful in these trials?

Across pooled adult studies, cinnarizine 25 mg produced meaningful reductions in nausea scores and frequency of vertigo episodes compared with placebo.

Head‑to‑head data showed cinnarizine often performed better than dimenhydrinate and meclizine for vestibular symptom control in short‑term settings, with faster or larger decreases in dizziness severity for some patient groups.

Safety Observations

What safety signals should clinicians and travelers watch for?

Trials consistently noted dose‑related sedation and daytime drowsiness as the most common adverse effects.

Longer courses—measured in weeks to months—were associated with a small but real risk of extrapyramidal symptoms, especially in older adults or people with Parkinsonian predisposition.

Most RCTs were short‑term, so randomized long‑term safety data remain limited and pharmacovigilance case series continue to report rare movement disorders after months of use.

Clinical Mechanism Of Action

Layman’s Explanation

How does Stugeron make motion and dizziness feel better?

Cinnarizine reduces abnormal signals from the inner ear that drive motion‑sickness and dizziness and improves microvascular blood flow in the brain and peripheral tissues, which helps reduce nausea and vertigo.

Scientific Breakdown

What does the science say about how cinnarizine works?

Cinnarizine is classified under ATC N07CA02 as a calcium‑channel blocker active in vestibular pathways that dampens hyperactive vestibular input.

Receptor And Channel Effects

Which channels and receptors are involved?

The drug antagonizes T‑type and L‑type calcium channels in vestibular hair cells and vascular smooth muscle, reducing excessive vestibular afferent firing and producing microvascular vasodilation.

It also has antihistaminic and mild anticholinergic activity that contributes to its antiemetic properties.

CNS Penetration And Pharmacokinetics

How fast does it act and why does it make people sleepy?

Oral 25 mg tablets are absorbed systemically and undergo primarily hepatic metabolism with CYP2D6 implicated, so caution is advised in hepatic impairment.

Central nervous system penetration explains the sedative side effects and the typical onset for motion prophylaxis within 1–2 hours, supporting dosing about two hours before travel and repeat dosing every eight hours as clinically used.

Scope Of Approved And Off‑Label Use

United States Approvals

Is Stugeron an FDA‑labeled product in the United States?

The United States does not have a broad FDA‑registered Stugeron presence, and cinnarizine is not widely registered on US public formularies.

Because of limited formal availability, US clinicians more commonly use meclizine, dimenhydrinate, or promethazine for similar indications.

Notable Off‑Label Trends

How do clinicians use cinnarizine where it is available?

Internationally, clinicians prescribe cinnarizine off‑label for chronic vestibular hypofunction, migraine‑associated vertigo, and microcirculatory cerebral complaints.

Longer maintenance therapy for chronic vertigo often extends for weeks to months despite limited long‑term RCT data, and pediatric use is typically reserved for children five years and older with adjusted dosing.

Dosage Strategy

General Dosing

How should people take Stugeron for travel or vertigo?

The most common tablet strength is 25 mg.

For motion prophylaxis, a single 25 mg dose is taken about two hours before travel with repeats every eight hours if needed for short‑term use.

For symptomatic vertigo or vestibular disorders, typical prescribing is 25 mg three times daily (75 mg/day total) with periodic reassessment.

Condition‑Specific Dosing

What are condition examples and dosing adjustments?

Motion sickness: one 25 mg dose pre‑travel; short course only.

Vestibular hypofunction/vertigo: 25 mg three times daily, often continued for several weeks under review.

Cerebral or peripheral circulatory complaints: commonly 25 mg two to three times daily depending on clinician judgment and response.

Pediatric Adjustments

Can children use cinnarizine?

Not recommended under five years of age.

Children aged five to twelve may use 12.5 mg two to three times daily per product guidance in markets where pediatric formulations exist.

Elderly And Organ Impairment

How should older adults and those with liver problems be managed?

Elderly patients should receive lower doses and closer monitoring because of increased risks of sedation, confusion, and extrapyramidal symptoms.

Hepatic impairment requires dose reduction and clinical judgment given CYP2D6 metabolism.

Safety Protocols

Contraindications

Who should not take Stugeron?

Absolute contraindications include known allergy to cinnarizine or excipients, porphyria, severe hepatic impairment, and pregnancy or breastfeeding unless benefits clearly outweigh risks.

Relative contraindications include Parkinson’s disease, elderly patients, severe renal disease, and concurrent use with CNS depressants or alcohol.

Adverse Effects

What side effects are most common and which are serious?

Common adverse effects are drowsiness, dry mouth, mild gastrointestinal upset, headache, fatigue, and potential weight gain with prolonged use.

Moderate problems can include restlessness and cognitive slowing.

Rare but serious reactions include extrapyramidal symptoms such as drug‑induced parkinsonism and dystonia, and seizures in overdose.

Monitoring Recommendations

What monitoring should a prescriber plan?

Baseline review for movement‑disorder history is important before starting extended therapy.

For courses longer than several weeks, periodic assessment for extrapyramidal signs and liver function monitoring when clinically indicated are recommended.

Counsel patients to avoid driving or operating machinery until they know how the drug affects them.

Interaction Mapping

Food Interactions

Will food change how cinnarizine works?

No major food interactions are documented in product summaries, though fatty meals may delay or alter absorption timing.

Patients may take cinnarizine with or without food according to tolerance, and consistent timing relative to meals helps predict effects.

Drug Combinations To Avoid

Which drugs raise concern when combined with cinnarizine?

CNS depressants including alcohol, benzodiazepines, opioids, and sedating antihistamines increase sedation risk when taken with cinnarizine.

Concurrent antipsychotics or other dopamine‑antagonists can amplify extrapyramidal risks.

Strong CYP2D6 inhibitors or inducers may alter cinnarizine exposure and warrant caution.

Practical Management Tips

What can pharmacists advise to reduce risk?

Review the full medication list for Parkinsonian predisposition and avoid alcohol while taking cinnarizine.

Reduce dose or stop the drug if excessive sedation or new movement symptoms occur and consider switching to alternatives such as meclizine or dimenhydrinate if risks outweigh benefits.

Patient Experience Analysis

Survey Data

How do patients say Stugeron works for travel and vertigo?

Published surveys and real‑world registries report high satisfaction for travel prophylaxis and symptomatic vertigo control, with many patients noting rapid relief from nausea and decreased dizziness frequency after a 25 mg dose.

Adherence is affected by tolerability—drowsiness and daytime sleepiness are the most common reasons for stopping longer courses.

Forum Trends

What do online forums and social media reveal?

Common patient themes include advice on timing before travel, reports of vivid dreams and morning grogginess, and questions about combining cinnarizine with other antiemetics.

Anecdotal reports of movement disorders after months of therapy appear in forums, mirroring pharmacovigilance alerts and underscoring the need for clinician follow‑up during maintenance use.

Where available OTC, many users compare Stugeron favorably with dimenhydrinate and meclizine for vestibular control while noting heavier sedation in some cases.

Distribution And Pricing Landscape

Where is Stugeron sold and how much does it cost?

Global availability varies markedly by market; Stugeron (cinnarizine 25 mg) is widely supplied in Europe and Canada and often sold OTC in many of those countries.

Packaging commonly includes blister packs of 10–30 tablets and boxes of 100 in some regions, and multiple manufacturers and generics keep prices competitive in those markets.

Australia lists cinnarizine as not registered on public formulary, and the United States shows limited market presence compared with meclizine and dimenhydrinate.

In OTC markets, single‑digit USD cost per 25 mg generic tablet is common in bulk purchases, while branded Stugeron typically costs more.

Online pharmacies and cross‑border sellers add variability to access and price.

In our online pharmacy, Stugeron is available without a prescription, with discreet delivery to United States in 5‑14 days.

Alternative Options

Comparison Table

Which drugs are reasonable alternatives to cinnarizine?

Key alternatives include dimenhydrinate (Dramamine), meclizine (Bonine/Antivert), promethazine (Phenergan), and betahistine (Serc for Ménière’s).

Pros And Cons

How do these alternatives stack up in practice?

Cinnarizine offers strong vestibular suppression and microvascular effects but carries higher sedation risk and extrapyramidal potential with long‑term use.

Meclizine is often promoted as less drowsy, has a longer half‑life, and is convenient for single daily dosing for motion sickness.

Dimenhydrinate is a reliable acute antiemetic with notable sedation and is widely available OTC as Dramamine.

Promethazine is potent but has significant anticholinergic and sedative burden and is prescription‑only in many markets.

Betahistine targets vertigo associated with Ménière’s but works through a different mechanism and has mixed evidence across trials.

Choosing between options involves balancing efficacy for vertigo treatment with patient tolerance for sedation and the safety profile, especially in older adults.

Regulatory Status

How is cinnarizine regulated around the world?

Cinnarizine is variably regulated and is widely available OTC in many European countries and the United Kingdom for motion sickness, while Canada supplies it OTC or Rx depending on province and product.

Romania and several EU nations list Stugeron 25 mg as registered and available in blister packs of common sizes.

Australia does not list cinnarizine broadly on its public formulary, and the United States lacks a broad FDA‑registered Stugeron presence.

Regulatory labels in OTC markets usually limit indications to short‑term motion sickness, while vertigo and circulatory claims may require prescription status in some jurisdictions.

Post‑marketing surveillance in countries with wide use has informed updated contraindications and monitoring guidance for Parkinson’s disease and elderly patients.

Consolidated FAQ

Is Stugeron the same as cinnarizine?

Yes; Stugeron is a brand name for the INN cinnarizine, commonly supplied as 25 mg tablets.

Can I use it for travel?

Yes; a typical travel dose is 25 mg about two hours before travel, repeating every eight hours if needed for short‑term use.

Is Stugeron available OTC?

Availability varies by country—mostly OTC in many EU and UK markets and in parts of Canada, but the United States does not have broad registered Stugeron distribution.

Are there major risks?

Sedation is the most frequent adverse effect; prolonged use may cause extrapyramidal symptoms and should be avoided or monitored in Parkinson’s disease and older adults.

Can children use it?

Not recommended under five years; ages five to twelve typically use 12.5 mg two to three times daily where pediatric guidance and formulations exist.

What about pregnancy and breastfeeding?

Use is generally avoided in pregnancy and breastfeeding unless the potential benefit outweighs risk and a clinician advises otherwise.

How are missed doses and overdose handled?

Take a missed dose as soon as remembered unless it is close to the next dose and do not double doses; overdose can cause severe drowsiness, confusion, and seizures—seek immediate medical attention.

Visual Guide

Tablet Appearance & Packaging

What does Stugeron look like and how is it packaged?

Stugeron/cinnarizine 25 mg tablets are typically small and round or oblong and are sold in blister packs of 10, 15, 20, 25, or 30, with some markets offering boxes of 100 tablets.

Dosing Timeline Visual (Recommended)

How should a dosing timeline be displayed for patients?

For travel, show a clock with a single 25 mg dose two hours before departure and optional repeats every eight hours if needed.

For vertigo maintenance, show 25 mg at morning, midday, and evening with a checkpoint at two to four weeks for reassessment.

Safety Checkpoints

What safety icons should be included on counseling cards?

Include icons and short labels for: no driving until you know effects, avoid alcohol, stop and contact clinician if new involuntary movements occur, and avoid use in pregnancy unless advised.

Storage And Transport

How should Stugeron be stored?

Store at room temperature in a cool, dry place away from direct sunlight and moisture; do not refrigerate.

Keep out of reach of children and keep blister packs in their original packaging to protect from humidity.

What about travel and transport precautions?

Carry medication in original packaging or with a copy of product labeling to assist with customs questions in jurisdictions where Stugeron is unregistered.

Avoid prolonged exposure to high heat, for example in checked luggage on hot flights, to prevent tablet degradation.

For disposal, follow local medicine‑take‑back protocols rather than flushing.

Guidelines For Proper Use

Prescriber Checklist

What should prescribers confirm before starting cinnarizine?

Verify the indication, review history of Parkinsonism or movement disorders, assess liver function and potential drug interactions, confirm patient age and pregnancy/lactation status, and document a baseline neurological exam when planning extended therapy.

Patient Counseling Points

What should patients be told at the pharmacy counter?

Advise taking 25 mg about two hours before travel for acute use and following the prescribed TID schedule for chronic vestibular problems, with re‑evaluation planned.

Warn that significant drowsiness can occur, instruct patients not to drive until they know how the medication affects them, and counsel them to avoid alcohol.

Tell patients to report any new involuntary movements, stiffness, or unexpected cognitive changes immediately.

Follow‑Up And Discontinuation Strategy

How and when should therapy be reviewed or stopped?

Reassess benefit versus adverse effects within two to four weeks for chronic users and taper or discontinue if extrapyramidal signs or intolerable sedation occur.

Consider alternative options such as meclizine or dimenhydrinate when side effects or risks outweigh benefits for an individual patient.

Delivery Across United States

City	Region	Delivery Time
New York	Northeast	5-7 days
Los Angeles	West Coast	5-7 days
Chicago	Midwest	5-7 days
Houston	South	5-7 days
Phoenix	Southwest	5-7 days
Philadelphia	Northeast	5-7 days
San Antonio	South	5-9 days
San Diego	West Coast	5-7 days
Dallas	South	5-7 days
San Jose	West Coast	5-9 days
Austin	South	5-9 days
Jacksonville	South East	5-9 days
Fort Worth	South	5-9 days
Columbus	Midwest	5-9 days